XHKG
9966
Market cap998mUSD
Oct 07, Last price
8.09HKD
1D
-3.46%
1Q
11.13%
IPO
-43.43%
Name
Alphamab Oncology
Chart & performance
P/E
—
P/S
12.12
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.67%
Rev. gr., 5y
163.99%
Revenues
552m
-13.83%
Net income
-111m
L
CFO
-122m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Key people
Ting Xu
Executive Chairman of the Board, Chief Executive Officer · since 2019
Yang Liu
Vice President - Corporate Operations, Executive Director · since 2019
Jing Han
Chief Commercial Officer · since 2021
Lok Yee Chan
Joint Company Secretary · since 2020
Qiulan Cheng
Joint Company Secretary · since 2024
Man Cho
Non-Executive Director · since 2024
Xiang Gao
Non-Executive Independent Director · since 2025
Non-Executive Independent Director · since 2019
Yan Ki Wong
Non-Executive Independent Director · since 2025
Dong Wu
Non-Executive Independent Director · since 2019
Legal address
c/o Trust Company (Cayman) Limited
Criket Squar, Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
KY
Criket Squar, Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
KY
Headquarters
Rooms 401 & 501, Building C23
No. 218 Xinghu Street
Suzhou Industrial Park
Suzhou 234000
CN
No. 218 Xinghu Street
Suzhou Industrial Park
Suzhou 234000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||